We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 4TO market cap is 12.16M. The company's latest EPS is USD and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 281k | 493k | 577k | 529k | 895k |
| Operating Income | -921k | -674k | -9.73M | -26.18M | -26.65M |
| Net Income | -957k | -587k | -11.69M | -26.39M | -26.3M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 0 | 673k | 10.04M | 20.24M | 15.41M |
| Total Liabilities | 0 | 3.41M | 3.68M | 6.15M | 12.16M |
| Total Equity | 0 | -2.74M | 6.36M | 14.1M | 3.25M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -416k | -468k | -3.22M | -14.77M | -21.94M |
| Investing | N/A | -9k | 1.2M | -658k | -1.9M |
| Financing | 423k | 396k | 10.61M | 23.94M | 14.23M |
| Market Cap | 12.16M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 14.83M |
| Average Volume (1 week) | 33.45k |
| Average Volume (1 Month) | 30.32k |
| 52 Week Change | -70.50% |
| 52 Week High | 5.20 |
| 52 Week Low | 0.751 |
| Spread (Intraday) | 0.05 (5.92%) |
| Company Name | Mainz Biomed NV |
| Address |
keizersgracht 391a amsterdam, north holland |
| Website | https://www.mainzbiomed.com |
| Industry | testing laboratories (8734) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
